Identification

Generic Name
Enviomycin
DrugBank Accession Number
DB08993
Background

Cyclic basic peptide related to viomycin. It is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 685.69
Monoisotopic: 685.325584661
Chemical Formula
C25H43N13O10
Synonyms
  • Enviomicina
  • Enviomycin
  • Enviomycine
  • Enviomycinum
  • Tuberactinomycin N

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcenocoumarolThe risk or severity of bleeding can be increased when Enviomycin is combined with Acenocoumarol.
Bacillus calmette-guerin substrain russian BCG-I live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Enviomycin.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Enviomycin.
DicoumarolThe risk or severity of bleeding can be increased when Enviomycin is combined with Dicoumarol.
EstetrolThe therapeutic efficacy of Estetrol can be decreased when used in combination with Enviomycin.
FluindioneThe risk or severity of bleeding can be increased when Enviomycin is combined with Fluindione.
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Enviomycin.
MagnesiumThe serum concentration of Magnesium can be decreased when it is combined with Enviomycin.
PhenindioneThe risk or severity of bleeding can be increased when Enviomycin is combined with Phenindione.
PhenprocoumonThe risk or severity of bleeding can be increased when Enviomycin is combined with Phenprocoumon.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Enviomycin sulfate67846BXW6553760-33-1DZKQVWCTFCSEKF-QOEBQMAPSA-N
International/Other Brands
Tuberactin (Asahi Kasei Pharma)

Categories

ATC Codes
J04AB06 — Enviomycin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Cyclic peptides
Alternative Parents
Diazinanes / 1,3-aminoalcohols / Cyclic carboximidic acids / Secondary alcohols / 1,2-aminoalcohols / Guanidines / Isoureas / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Carboximidamides
show 6 more
Substituents
1,2-aminoalcohol / 1,3-aminoalcohol / 1,3-diazinane / Alcohol / Aliphatic heteromonocyclic compound / Amine / Azacycle / Carboximidamide / Carboximidic acid / Carboximidic acid derivative
show 19 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
  • Mycobacterium tuberculosis

Chemical Identifiers

UNII
XU299C23A2
CAS number
33103-22-9
InChI Key
HPWIIERXAFODPP-GHBBWTPBSA-N
InChI
InChI=1S/C25H43N13O10/c26-3-1-16(41)10(27)5-17(42)33-12-6-31-23(47)18(11-2-4-30-24(28)37-11)38-20(44)13(7-32-25(29)48)34-21(45)14(8-39)36-22(46)15(9-40)35-19(12)43/h7,10-12,14-16,18,39-41H,1-6,8-9,26-27H2,(H,31,47)(H,33,42)(H,34,45)(H,35,43)(H,36,46)(H,38,44)(H3,28,30,37)(H3,29,32,48)/b13-7-/t10-,11-,12+,14+,15+,16-,18+/m1/s1
IUPAC Name
(3R,4R)-3,6-diamino-N-[(3S,6Z,9S,12S,15S)-3-[(4R)-2-amino-3,4,5,6-tetrahydropyrimidin-4-yl]-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentaazacyclohexadecan-15-yl]-4-hydroxyhexanamide
SMILES
[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CNC1=O)NC(=O)C[C@@H](N)[C@H](O)CCN)=C\NC(N)=O

References

Synthesis Reference

U.S. Patent 3,892,732.

General References
Not Available
KEGG Drug
D07897
PubChem Compound
20055267
PubChem Substance
310264954
ChemSpider
16736480
ChEMBL
CHEMBL2146142
ZINC
ZINC000169291448
Drugs.com
Drugs.com Drug Page
Wikipedia
Enviomycin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.56 mg/mLALOGPS
logP-3.5ALOGPS
logP-12ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)8.71ChemAxon
pKa (Strongest Basic)10.52ChemAxon
Physiological Charge3ChemAxon
Hydrogen Acceptor Count15ChemAxon
Hydrogen Donor Count15ChemAxon
Polar Surface Area392.86 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity161.87 m3·mol-1ChemAxon
Polarizability65.92 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at June 16, 2014 15:39 / Updated at January 02, 2022 12:00